PRC
MRVI icon

Pearl River Capital’s Maravai LifeSciences MRVI Stock Holding History

Pearl River Capital’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-11,155
Closed -$156K – 570
2023
Q1 		$156K Buy
+11,155
New +$160K 0.02% 466
2022
Q1 		– Sell
-5,625
Closed -$236K – 504
2021
Q4 		$236K Buy
+5,625
New +$228K 0.06% 344

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Pearl River Capital's MRVI Position: Q2 2023 in Review

Pearl River Capital sold out of Maravai LifeSciences (MRVI) in Q2 2023, closing a stake of 11,155 shares — an estimated $156K sold.

Pearl River Capital first reported a position in MRVI in Q4 2021 and held it in 2 quarters. The position peaked at $236K in Q4 2021. 221 funds tracked by Wall St. Rank hold MRVI as of Q2 2023.

  • Pearl River Capital reported no remaining Maravai LifeSciences position as of Q2 2023 after selling out during the quarter.
  • Pearl River Capital sold 11,155 Maravai LifeSciences shares in Q2 2023, an estimated $156K.
  • Pearl River Capital first reported a position in Maravai LifeSciences in Q4 2021 and held it in 2 quarters.
  • Pearl River Capital's Maravai LifeSciences position peaked at $236K in Q4 2021.
  • 221 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2023.

Based on Pearl River Capital's 13F filing for Q2 2023, filed 11 Aug 2023.